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Tau proteins were detected in human brain using two polyclonal antibodies: anti-paired helical filaments and anti-human 
native tau proteins. Both antisera detected identically the normal set of tau proteins in control brains. Moreover they 
detected two abnormal tau variants of 64 and 69 kDa exclusively in brain areas showing neurofibrillary tangles and senile 
plaques. Tau 64 and 69 were abnormally phosphorylated as revealed by the decrease in their molecular mass observed 
after alkaline phosphatase treatment. Therefore, tau 64 and 69 are specific markers of the neurofibrillary degeneration 
of the Alzheimer type and might be useful tools for studying the first pathological events that lead to neuronal death. 
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1. INTRODUCTION 
Alzheimer’s disease is a neurodegenerative brain 
disorder characterized by a dementia accompanied 
by a severe loss of large cortical neurons, the ac- 
cumulation of PHF in the degenerating neurons 
and extracellular amyloid deposits [ 11. 
The analysis of PHF has been undertaken in re- 
cent years in order to obtain clues about the 
etiopathogenesis of AD. Many converging results 
have shown that microtubule associated tau pro- 
teins are most probably the major structural pro- 
teins of PHF [2-S]. An abnormal phosphorylation 
of tau proteins during AD has been suggested 
[6,9,10], but this point is still being discussed since 
there is no direct biochemical evidence for such an 
abnormality [ 1 I]. 
Up to now, studies using anti-tau or anti-PHF 
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antibodies failed to observe new variants among 
the set of tau proteins in Alzheimer brains. 
We present here a comparison of the tau profile 
in normal and Alzheimer brain homogenates, us- 
ing well characterized antisera against PHF that 
detect exclusively tau proteins and against au pro- 
teins from human origin. These immunological 
tools reveal the presence of two pathological forms 
of tau proteins which are abnormally phospho- 
rylated, in brain areas showing neurofibrillary 
degeneration of the Alzheimer type. 
2. MATERIALS AND METHODS 
Tau proteins were detected in SDS homogenates from 
Alzheimer brains (10 brains of definite AD, aged between 55 
and 85) and 10 age-matched control brains. The diagnosis of 
Alzheimer’s disease was established according to NINCDS- 
ADRDA classification [12]. Patients with Alzheimer’s disease 
were 55, 60 and 62 years old and patients with senile dementia 
of the Alzheimer type were 75-85 years old. Controls were 
53-98 years old and died of non-neurological diseases. Dif- 
ferent regions were simultaneously studied for the 
neuropathologic diagnosis and for biochemical analysis, as in 
[3]. Brain tissue was homogenized in the Laemmli sample buf- 
fer [13] 1: 10 (w/v), and heat treated. Brain proteins were 
separated by SDS-PAGE and electrophoretically transferred to 
nitrocellulose paper for tau immunodetection as in [14]. After 
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a dialysis against buffer containing 50 mM Tris, pH 8.3, 
50 mM NaCl, 1 mM Mg and 0.2 mM DTT, some samples were 
dephosphorylated using the calf intestine,alkaline phosphatase 
(Boehringer Mannheim) at 100 U/ml [15]. The enzyme action 
was stopped by heating after addition of an equal volume of the 
Laemmli sample buffer. The anti-PHF whose properties at the 
light microscopic, electron microscopic and biochemical evels 
have already been described [3,14,16], was used at l/200. The 
anti-tau antiserum was obtained by immunizing a rabbit with 
heat-stable human tau proteins purified with a preparative SDS- 
PAGE, and was used at l/10000. 
3. RESULTS 
3.1. Immunoblot detection C$ tau proteins in 
normal brain and Alzheim&s disease brain 
The electrophoretic profile of tau proteins from 
the normal human brain consists of four bands be- 
tween 45 and 62 kDa (fig.1). Our anti-PHF and 
anti-tau detect identically these four proteins. 
In Alzheimer brain, in addition to the normal set 
of tau proteins, two bands at 64 and 69 kDa were 
stained (lanes 1, 3 and 9). Tau 64 and 69 were 
always present together in regions with 
neurofibrillary degeneration while they were ab- 
sent from regions without neurofibrillary tangles 
and neuritic plaques. Indeed, they were detected in 
temporal (lane l), frontal (lane 3), parietal and oc- 
cipital cortex, but were never found in caudate 
nucleus (lane 4), cerebellum, spinal cord and 
thalamus. Tau 64 and 69 detection was generally 
strong in the temporal, lower in the frontal and 
weak in the occipital cortex which often contains 
less NFT and SP. The staining appeared increased 
in Alzheimer brains having an early onset. 
Homogenates of AD brain contained a diffuse 
smear of immunoreactive material throughout the 
running gel (lanes 1, 3, and 9). The intensity of this 
background was proportional to the immunola- 
belling of the two pathological variants (cf. lanes 
1 and 3). We also found tau 64 and 69 in a frontal 
biopsy (lane 7) of a %-year-old patient who began 
to develop an unusual dementia with frontal 
clinical signs. Their detection was stronger than in 
all the autopsic pieces studied up to now (cf. lane 
7 with lanes 1, 3, 9). The histological study re- 
vealed that many NFT and SP were present in this 
tissue. 
Tau 64 and 69 were never found in the different 
areas of control brains (lanes 2 and 6). Even in the 
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Fig.1. Immunoblot detection of tau proteins with antihuman 
tau on total brain protein from controls and patients with 
Alzheimer’s disease. 25 ~1 of SDS homogenates (1: 10, w/v) 
were loaded in each well. Once separated by SDS-PAGE, brain 
proteins were electrophoretically transferred on nitrocellulose 
sheets. Then, the anti-tau was added at l/lOCCKl. Lanes: 1, 
temporal cortex from a 55-year-old Alzheimer patient; 2, 
temporal cortex from a 53-year-old control; 3, frontal cortex 
from a 77-year-old Alzheimer patient; 4, caudate nucleus from 
a ‘I&year-old Alzheimer patient; 5, hippocampus from an 
IO-year-old control; 6, frontal cortex from a 62-year-old 
control; 7, frontal biopsy from a 58-year-old Alzheimer patient 
(note that there is much more immunoreactive tau 64 and 69 
than in the other Alzheimer homogenates); 8, temporal cortex 
from a 75-year-old Alzheimer patient after a 5 h incubation 
with the calf intestine alkaline phosphatase (100 U/ml at 37°C). 
Tau 64 and 69 disappear and the tau profile becomes,similar to 
a control; 9, the same sample prior, to dephosphorylation. Tau 
64 and 69 have a high molecular mass which is due to their 
abnormal phosphorylation. They are only detected in brain 
areas showing NFT and SP and are therefore reliable markers 
of the neurofibrillary degeneration of the Alzheimer type. 
64 and 69 were never detected. Nevertheless, tau 64 
and 69 were found in the hippocampus from an 
80-year-old control (lane 5). The histological study 
of this tissue revealed the presence of NFT and SP. 
3.2. Effect of phosphatase treatment 
In order to determine’if the slow electrophoretic 
mobility of tau 64 and 69 was due to a modifica- 
tion of their molecular mass after an abnormal 
phosphorylation, we have dephosphorylated a cor- 
tical brain extract from an Alzheimer patient. 
After 5 h of incubation with the alkaline 
phosphatase at 37”C, the two pathological variants 
disappeared (lane 8). As a control, the same sam- 
ple was incubated during 5 h with the same 
amount of phosphatase inactivated by heating 
(lOO’C, 15 min): tau 64 and 69 were still detected 
(lane 8). 
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4. DISCUSSION 
Antisera against PHF and against human tau 
proteins have already been extensively used for 
neuropathologic studies at the light and electron 
microscopic levels [3,14,16] and they are very sen- 
sitive tools for the immunohistochemical detection 
of NFT and SP. Besides, they give identical tau 
profiles and are therefore suitable for a tau im- 
munodetection. 
Our study with these antisera led us to find two 
abnormal variants of tau proteins that are only 
detected in brain areas with NFT and SP. They 
were always present in cortical areas from the 10 
Alzheimer patients studied. The staining intensity 
of tau 64 and 69 was stronger in the regions which 
are mostly affected during the disease (temporal 
cortex). The tau 64 and 69 detection was propor- 
tional to the smears which probably correspond to 
the partial dissociation of tau aggregates in PHF 
[3,5]. Tau 64 and 69 were generally more strongly 
detected in brain homogenates from Alzheimer pa- 
tients having an early onset. Their detection was 
also stronger in a biopsy (mean stage of the 
disease) than in all the autopsic pieces (ultimate 
stage of the disease). 
In contrast, they were never found in the 10 con- 
trol brains even if very old, except in the hip- 
pocampus of an 80-year-old patient, which 
contained NFT and SP. 
Therefore tau 64 and 69 are reliable markers of 
the neurofibrillary degeneration of the Alzheimer 
type. 
We analyzed the state of phosphorylation of 
these proteins, since an abnormal phosphorylation 
of tau during AD has been suggested [6,9,10]. The 
incubation of tau proteins from an Alzheimer 
brain with alkaline phosphatase during 5 h 
dramatically changed the tau staining pattern: the 
two pathological variants disappeared. Therefore, 
since the apparent molecular mass of tau proteins 
depends upon their phosphorylation state 
[9,10,15], we conclude that the abnormal 
molecular mass of tau 64 and 69 is due to a 
dysfunction in the regulation of tau phos- 
phorylation. 
Our results show that during AD there is a 
pathological process which results in the formation 
of abnormal tau species easily detectable and 
quantifiable. Their strong detection in the biopsy is 
in favour of their early presence during the 
neurodegeneration process. Moreover, their solu- 
bilization with the normal set of tau proteins,using 
mild SDS extractions leads us to think that they are 
not yet incorporated in PHF which are SDS-in- 
soluble [17]. Thus, the abnormal phosphorylation 
might be the trigger that precedes and induces their 
incorporation in the PHF structure. Consequently, 
their further characterization and the search for 
experimental conditions able to produce such ab- 
normal tau proteins might be useful to establish an 
in vitro model of nerve cell degeneration. For ex- 
ample, they might be produced in nerve cell 
cultures after the addition of aluminium salts [ 181, 
or in cells transfected with the Cu,Zn-superoxide 
dismutase gene [19]. This might be very suitable 
for the study of the early events that lead to the 
neurofibrillary degeneration and might help in the 
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